Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Ketoprofen
- Accession Number
- DB01009 (APRD01059, DB05823, DB05335)
- Type
- Small Molecule
- Groups
- Approved, Vet Approved
- Description
Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
- Structure
Structure for DB01009 (Ketoprofen)
- Synonyms
- 2-(3-Benzoylphenyl)propionic acid
- 3-Benzoyl-alpha-methylbenzeneacetic acid
- 3-Benzoyl-α-methylbenzeneacetic acid
- 3-Benzoylhydratropic acid
- Ketoprofen
- L'Acide (benzoyl-3-phenyl)-2-propionique
- m-Benzoylhydratropic acid
- Orudis (tn)
- Product Ingredients
Ingredient UNII CAS InChI Key Ketoprofen sodium 5R10M39KS7 57495-14-4 OAPDLBHLMVYMCW-UHFFFAOYSA-M - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ketoprofen Capsule 50 mg Oral Aa Pharma Inc 1989-12-31 Not applicable Canada 
Ketoprofen SR Tablet, extended release 200 mg Oral Aa Pharma Inc 1995-12-31 Not applicable Canada Ketoprofen Suppositories Suppository 100 mg Rectal Pharmel Inc 1998-06-04 Not applicable Canada Ketoprofen Suppositories Suppository 50 mg Rectal Pharmel Inc Not applicable Not applicable Canada Ketoprofen-E Tablet, delayed release 100 mg Oral Aa Pharma Inc 1989-12-31 Not applicable Canada Ketoprofen-E Tablet, delayed release 50 mg Oral Aa Pharma Inc 1989-12-31 Not applicable Canada Ketoprofen-E Ect 100mg Tablet, delayed release 100 mg Oral Pro Doc Limitee 1996-12-31 2009-07-23 Canada Ketoprofen-E Ect 50mg Tablet, delayed release 50 mg Oral Pro Doc Limitee 1995-12-31 2009-07-23 Canada Ketoprofen-SR - Srt 200mg Tablet, extended release 200 mg Oral Pro Doc Limitee 1997-09-18 2009-07-23 Canada Novo-keto Suppositories 100mg Suppository 100 mg Rectal Novopharm Limited 1996-12-31 2005-08-10 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ketoprofen Capsule 75 mg/1 Oral A S Medication Solutions 1993-01-01 2017-06-20 US 
Ketoprofen Capsule 50 mg/1 Oral Mylan Pharmaceuticals 1997-01-15 Not applicable US Ketoprofen Capsule 50 mg/1 Oral Teva 1993-01-01 Not applicable US 
Ketoprofen Capsule 50 mg/1 Oral Aidarex Pharmaceuticals LLC 1993-01-01 Not applicable US Ketoprofen Capsule 75 mg/1 Oral Rebel Distributors 2011-01-18 Not applicable US Ketoprofen Capsule 50 mg/1 Oral bryant ranch prepack 1993-01-01 Not applicable US Ketoprofen Capsule 50 mg/1 Oral Avera Mc Kennan Hospital 2015-10-28 Not applicable US Ketoprofen Capsule 50 mg/1 Oral H.J. Harkins Company 2011-01-18 Not applicable US Ketoprofen Capsule, extended release 200 mg/1 Oral Physicians Total Care, Inc. 2009-06-23 Not applicable US 
Ketoprofen Capsule 50 mg/1 Oral Stat Rx USA 2011-01-18 Not applicable US - Unapproved/Other Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Vopac - Ketoprofen, Lidocaine Hydrochloride Pac Kit Sircle Laboratories, Llc 2015-03-01 2017-07-13 US - International/Other Brands
- Actron / Alrheumun (Teofarma) / Capisten (Kissei) / Epatec (Zeria Shinyaku) / Fastum (Menarini) / Menamin (Daiko Seiyaku) / Orudis (Abbott) / Orudis KT (Sanofi) / Orugesic (Sanofi) / Oruvail (Wyeth) / Oscorel (Sanofi) / Profenid (Sanofi) / Toprec (Sanofi)
- Categories
- Acids, Carbocyclic
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antirheumatic Agents
- Central Nervous System Agents
- Cyclooxygenase Inhibitors
- Cytochrome P-450 CYP2C8 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C9 Substrates
- Enzyme Inhibitors
- Musculo-Skeletal System
- Peripheral Nervous System Agents
- Phenylpropionates
- Propionates
- Sensory System Agents
- UNII
- 90Y4QC304K
- CAS number
- 22071-15-4
- Weight
- Average: 254.2806
Monoisotopic: 254.094294314 - Chemical Formula
- C16H14O3
- InChI Key
- DKYWVDODHFEZIM-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
- IUPAC Name
- 2-(3-benzoylphenyl)propanoic acid
- SMILES
- CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Pharmacology
- Indication
For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
- Structured Indications
- Pharmacodynamics
Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
- Mechanism of action
The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Target Actions Organism UProstaglandin G/H synthase 1 inhibitorHuman AProstaglandin G/H synthase 2 inhibitorHuman UC-X-C chemokine receptor type 1 otherHuman - Absorption
Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
- Volume of distribution
- Not Available
- Protein binding
99% bound, primarily to albumin
- Metabolism
Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.
Reactions:
- Route of elimination
In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
- Half life
Conventional capsules: 1.1-4 hours
Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)
- Clearance
- Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]
- Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)]
- 0.08 L/kg/h
- 0.7 L/kg/h [alcoholic cirrhosis patients]
- Toxicity
LD50=62.4 mg/kg (rat, oral).
Symptoms of overdose include drowsiness, vomiting and abdominal pain.
Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Ketoprofen Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Ketoprofen is combined with 5-androstenedione. Experimental, Illicit Abciximab Ketoprofen may increase the anticoagulant activities of Abciximab. Approved Abiraterone The metabolism of Ketoprofen can be decreased when combined with Abiraterone. Approved Acebutolol Ketoprofen may decrease the antihypertensive activities of Acebutolol. Approved Aceclofenac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Aceclofenac. Approved Acemetacin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Acemetacin. Approved Acenocoumarol Ketoprofen may increase the anticoagulant activities of Acenocoumarol. Approved Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ketoprofen. Approved, Vet Approved Aclarubicin Ketoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Ketoprofen. Approved Alclofenac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Aldosterone. Experimental Alendronic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid. Approved Aliskiren Ketoprofen may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alminoprofen. Experimental Alprenolol Ketoprofen may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Ketoprofen. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Amcinonide. Approved Amikacin Ketoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Vet Approved Amiloride Ketoprofen may decrease the antihypertensive activities of Amiloride. Approved Amiodarone The metabolism of Ketoprofen can be decreased when combined with Amiodarone. Approved, Investigational Amodiaquine The serum concentration of Amodiaquine can be increased when it is combined with Ketoprofen. Approved Amrubicin Ketoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level. Approved, Investigational Ancrod Ketoprofen may increase the anticoagulant activities of Ancrod. Investigational Andrographolide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Andrographolide. Investigational Androstenedione The risk or severity of adverse effects can be increased when Ketoprofen is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Ketoprofen is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Ketoprofen is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Anisodamine. Investigational annamycin Ketoprofen may decrease the excretion rate of annamycin which could result in a higher serum level. Investigational Antipyrine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine. Approved Antithrombin III human Ketoprofen may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Ketoprofen may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Apocynin. Investigational Apramycin Ketoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Ketoprofen is combined with Apremilast. Approved, Investigational Aprepitant The metabolism of Ketoprofen can be increased when combined with Aprepitant. Approved, Investigational Arbekacin Ketoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved Ardeparin Ketoprofen may increase the anticoagulant activities of Ardeparin. Approved, Withdrawn Argatroban Ketoprofen may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Ketoprofen may decrease the antihypertensive activities of Arotinolol. Approved Atamestane The risk or severity of adverse effects can be increased when Ketoprofen is combined with Atamestane. Investigational Atenolol Ketoprofen may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketoprofen. Approved Balsalazide Ketoprofen may increase the nephrotoxic activities of Balsalazide. Approved, Investigational Becaplermin Ketoprofen may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Ketoprofen may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Ketoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Benazepril is combined with Ketoprofen. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketoprofen. Approved Benorilate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benoxaprofen. Withdrawn Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Ketoprofen. Investigational Betamethasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Betamethasone. Approved, Vet Approved Betaxolol Ketoprofen may decrease the antihypertensive activities of Betaxolol. Approved Bevantolol Ketoprofen may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketoprofen. Approved, Investigational Bisoprolol Ketoprofen may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Ketoprofen may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Ketoprofen may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen. Approved Bucillamine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bucillamine. Investigational Bucindolol Ketoprofen may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bufexamac. Experimental Bufuralol Ketoprofen may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bumadizone. Experimental Bumetanide Ketoprofen may decrease the diuretic activities of Bumetanide. Approved Bupranolol Ketoprofen may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen. Approved Candoxatril The risk or severity of adverse effects can be increased when Candoxatril is combined with Ketoprofen. Experimental Capecitabine The metabolism of Ketoprofen can be decreased when combined with Capecitabine. Approved, Investigational Captopril The risk or severity of adverse effects can be increased when Captopril is combined with Ketoprofen. Approved Carbamazepine The metabolism of Ketoprofen can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Ketoprofen is combined with Carbaspirin calcium. Experimental Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketoprofen. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Ketoprofen. Approved, Vet Approved, Withdrawn Carteolol Ketoprofen may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Ketoprofen may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Castanospermine. Experimental Celiprolol Ketoprofen may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Ceritinib The serum concentration of Ketoprofen can be increased when it is combined with Ceritinib. Approved Certoparin Ketoprofen may increase the anticoagulant activities of Certoparin. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Ketoprofen. Approved, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketoprofen. Approved Cholecalciferol The metabolism of Ketoprofen can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Cilazapril is combined with Ketoprofen. Approved Cinoxacin Ketoprofen may increase the neuroexcitatory activities of Cinoxacin. Approved, Withdrawn Citric Acid Ketoprofen may increase the anticoagulant activities of Citric Acid. Nutraceutical, Vet Approved Clobetasol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol. Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ketoprofen. Vet Approved Cloranolol Ketoprofen may decrease the antihypertensive activities of Cloranolol. Experimental Clotrimazole The metabolism of Ketoprofen can be decreased when combined with Clotrimazole. Approved, Vet Approved Colesevelam Colesevelam can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortisone acetate. Approved Crisaborole The metabolism of Ketoprofen can be decreased when combined with Crisaborole. Approved Curcumin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Curcumin. Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ketoprofen. Experimental Cyclosporine Ketoprofen may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved D-Limonene The risk or severity of adverse effects can be increased when Ketoprofen is combined with D-Limonene. Investigational Dabigatran etexilate Ketoprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved Dabrafenib The serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib. Approved Dalteparin Ketoprofen may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Ketoprofen may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Ketoprofen may increase the anticoagulant activities of Darexaban. Investigational Daunorubicin Ketoprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Approved Deferasirox The risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Delapril is combined with Ketoprofen. Experimental Delavirdine The metabolism of Ketoprofen can be decreased when combined with Delavirdine. Approved Desirudin Ketoprofen may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin. Approved Desoximetasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone isonicotinate. Vet Approved Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ketoprofen. Approved Dextran Ketoprofen may increase the anticoagulant activities of Dextran. Approved, Vet Approved Dextran 40 Ketoprofen may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Ketoprofen may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Ketoprofen may increase the anticoagulant activities of Dextran 75. Approved Dibekacin Ketoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Ketoprofen. Approved, Vet Approved Dicoumarol Ketoprofen may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen. Approved Difluocortolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluocortolone. Approved Difluprednate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Ketoprofen. Approved Dihydrostreptomycin Ketoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Ketoprofen. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ketoprofen. Approved Dosulepin The metabolism of Ketoprofen can be decreased when combined with Dosulepin. Approved Doxorubicin Ketoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Approved, Investigational Drospirenone Ketoprofen may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Ketoprofen is combined with Droxicam. Approved Duvelisib The risk or severity of adverse effects can be increased when Ketoprofen is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when Ketoprofen is combined with E-6201. Investigational Edetic Acid Ketoprofen may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Ketoprofen may increase the anticoagulant activities of Edoxaban. Approved Efavirenz The metabolism of Ketoprofen can be decreased when combined with Efavirenz. Approved, Investigational Enalapril The risk or severity of adverse effects can be increased when Enalapril is combined with Ketoprofen. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketoprofen. Approved Enoxacin Ketoprofen may increase the neuroexcitatory activities of Enoxacin. Approved Enoxaparin Ketoprofen may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Ketoprofen. Experimental Epanolol Ketoprofen may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Ketoprofen is combined with Epirizole. Approved Epirubicin Ketoprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level. Approved Eplerenone Ketoprofen may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen. Approved Equilenin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilin. Approved Esmolol Ketoprofen may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone sulfate. Approved Etacrynic acid Ketoprofen may decrease the diuretic activities of Etacrynic acid. Approved Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ethenzamide. Experimental Ethyl biscoumacetate Ketoprofen may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etidronic acid. Approved Etofenamate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etofenamate. Approved Etravirine The metabolism of Ketoprofen can be decreased when combined with Etravirine. Approved Evening primrose oil The risk or severity of adverse effects can be increased when Ketoprofen is combined with Evening primrose oil. Approved exisulind The risk or severity of adverse effects can be increased when Ketoprofen is combined with exisulind. Investigational Felbinac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Felbinac. Experimental Fenbufen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fenbufen. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ketoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ketoprofen. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Feprazone. Experimental Ferulic acid Ketoprofen may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Ketoprofen. Approved Fleroxacin Ketoprofen may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Ketoprofen. Approved, Withdrawn Floxuridine The metabolism of Ketoprofen can be decreased when combined with Floxuridine. Approved fluasterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with fluasterone. Investigational Fluconazole The metabolism of Ketoprofen can be decreased when combined with Fluconazole. Approved Fludrocortisone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fludrocortisone. Approved Fluindione Ketoprofen may increase the anticoagulant activities of Fluindione. Investigational Flumequine Ketoprofen may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flumethasone. Approved, Vet Approved Flunixin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluorometholone. Approved Fluorouracil The metabolism of Ketoprofen can be decreased when combined with Fluorouracil. Approved Fluprednidene The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ketoprofen. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ketoprofen. Approved, Investigational Fluvastatin The metabolism of Ketoprofen can be decreased when combined with Fluvastatin. Approved Fluvoxamine The metabolism of Ketoprofen can be decreased when combined with Fluvoxamine. Approved, Investigational Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketoprofen. Approved, Nutraceutical, Vet Approved Fondaparinux Ketoprofen may increase the anticoagulant activities of Fondaparinux. Investigational Fondaparinux sodium Ketoprofen may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Ketoprofen. Experimental Formestane The risk or severity of adverse effects can be increased when Ketoprofen is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Fosinopril is combined with Ketoprofen. Approved Fosphenytoin The metabolism of Ketoprofen can be increased when combined with Fosphenytoin. Approved Framycetin Ketoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide Ketoprofen may decrease the diuretic activities of Furosemide. Approved, Vet Approved Gabexate Ketoprofen may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Ketoprofen may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketoprofen. Approved, Withdrawn Gemfibrozil The metabolism of Ketoprofen can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Ketoprofen may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Ketoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Ketoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Ketoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental GPX-150 Ketoprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level. Investigational Grepafloxacin Ketoprofen may increase the neuroexcitatory activities of Grepafloxacin. Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Ketoprofen is combined with Guacetisal. Experimental Haloperidol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Ketoprofen is combined with HE3286. Investigational Heparin Ketoprofen may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Higenamine. Investigational Hydralazine Ketoprofen may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen. Approved Hygromycin B Ketoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuproxam. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Ketoprofen is combined with Icatibant. Approved Idarubicin Ketoprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level. Approved Idraparinux Ketoprofen may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Imidapril is combined with Ketoprofen. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen. Approved Indenolol Ketoprofen may decrease the antihypertensive activities of Indenolol. Withdrawn Indinavir The metabolism of Ketoprofen can be decreased when combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Indoprofen. Withdrawn INNO-206 Ketoprofen may decrease the excretion rate of INNO-206 which could result in a higher serum level. Investigational Irbesartan The metabolism of Ketoprofen can be decreased when combined with Irbesartan. Approved, Investigational Isepamicin Ketoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Ketoprofen is combined with Isoxicam. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Ketoprofen is combined with Istaroxime. Investigational Kanamycin Ketoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Kebuzone. Experimental Ketoconazole The metabolism of Ketoprofen can be decreased when combined with Ketoconazole. Approved, Investigational Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Ketoprofen. Approved Labetalol Ketoprofen may decrease the antihypertensive activities of Labetalol. Approved Landiolol Ketoprofen may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketoprofen. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Ketoprofen. Investigational Leflunomide The metabolism of Ketoprofen can be decreased when combined with Leflunomide. Approved, Investigational Lepirudin Ketoprofen may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Ketoprofen may increase the anticoagulant activities of Letaxaban. Investigational Levobunolol Ketoprofen may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Ketoprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Ketoprofen. Approved Lisinopril The risk or severity of adverse effects can be increased when Lisinopril is combined with Ketoprofen. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisofylline. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Ketoprofen. Approved Lobeglitazone The metabolism of Ketoprofen can be decreased when combined with Lobeglitazone. Approved Lonazolac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam. Approved Losartan The metabolism of Ketoprofen can be decreased when combined with Losartan. Approved Lovastatin The metabolism of Ketoprofen can be decreased when combined with Lovastatin. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Loxoprofen. Approved Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ketoprofen. Approved, Investigational Lumacaftor The serum concentration of Ketoprofen can be decreased when it is combined with Lumacaftor. Approved Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Ketoprofen. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate. Approved Manidipine The metabolism of Ketoprofen can be decreased when combined with Manidipine. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Ketoprofen. Approved ME-609 The risk or severity of adverse effects can be increased when Ketoprofen is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ketoprofen. Approved Melagatran Ketoprofen may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen. Approved, Vet Approved Mepindolol Ketoprofen may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine Ketoprofen may increase the nephrotoxic activities of Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Ketoprofen is combined with Metamizole. Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Ketoprofen. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Methylprednisolone. Approved, Vet Approved Metipranolol Ketoprofen may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen. Approved Metoprolol Ketoprofen may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Metrizamide Ketoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level. Approved Micronomicin Ketoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Midostaurin The metabolism of Ketoprofen can be decreased when combined with Midostaurin. Approved Mifepristone The serum concentration of Ketoprofen can be increased when it is combined with Mifepristone. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketoprofen. Approved Mizoribine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Moexipril is combined with Ketoprofen. Approved Mofebutazone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mofebutazone. Experimental Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Ketoprofen. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid. Approved Nadolol Ketoprofen may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Ketoprofen may increase the anticoagulant activities of Nadroparin. Approved Nafamostat Ketoprofen may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Ketoprofen. Approved Nalidixic Acid Ketoprofen may increase the neuroexcitatory activities of Nalidixic Acid. Approved Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Ketoprofen. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Ketoprofen is combined with NCX 1022. Investigational Neamine Ketoprofen may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nemonoxacin Ketoprofen may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin Ketoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nepafenac. Approved Netilmicin Ketoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved Nicardipine The metabolism of Ketoprofen can be decreased when combined with Nicardipine. Approved Nifenazone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid. Approved Nimesulide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide. Approved, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nitroaspirin. Investigational Norfloxacin Ketoprofen may increase the neuroexcitatory activities of Norfloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Ketoprofen. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen. Approved Olsalazine Ketoprofen may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Omacetaxine mepesuccinate. Approved Omapatrilat The risk or severity of adverse effects can be increased when Omapatrilat is combined with Ketoprofen. Investigational Omeprazole The metabolism of Ketoprofen can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Orgotein The risk or severity of adverse effects can be increased when Ketoprofen is combined with Orgotein. Vet Approved Otamixaban Ketoprofen may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen. Approved Oxolinic acid Ketoprofen may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Ketoprofen may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Oxyphenbutazone. Withdrawn Pamidronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Paramethasone. Approved Paromomycin Ketoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Parthenolide. Investigational Pazufloxacin Ketoprofen may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Ketoprofen may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Ketoprofen may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentosan Polysulfate Ketoprofen may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Perindopril is combined with Ketoprofen. Approved Phenindione Ketoprofen may increase the anticoagulant activities of Phenindione. Approved Phenobarbital The metabolism of Ketoprofen can be increased when combined with Phenobarbital. Approved Phenprocoumon Ketoprofen may increase the anticoagulant activities of Phenprocoumon. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ketoprofen. Approved, Vet Approved Phenytoin The metabolism of Ketoprofen can be increased when combined with Phenytoin. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen. Approved, Investigational Pindolol Ketoprofen may decrease the antihypertensive activities of Pindolol. Approved Pipemidic acid Ketoprofen may increase the neuroexcitatory activities of Pipemidic acid. Experimental Pirarubicin Ketoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level. Investigational Piretanide Ketoprofen may decrease the diuretic activities of Piretanide. Experimental Pirfenidone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirfenidone. Investigational Piromidic acid Ketoprofen may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirprofen. Experimental Plazomicin Ketoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level. Investigational Plicamycin Ketoprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level. Approved, Withdrawn Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketoprofen. Approved Practolol Ketoprofen may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Ketoprofen. Approved Pranoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pranoprofen. Experimental Prasterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone. Approved, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednicarbate. Approved Prednisolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pregnenolone. Experimental Primidone The metabolism of Ketoprofen can be increased when combined with Primidone. Approved, Vet Approved Probenecid The serum concentration of Ketoprofen can be increased when it is combined with Probenecid. Approved Proglumetacin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Propacetamol. Approved Propranolol Ketoprofen may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ketoprofen. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ketoprofen. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Ketoprofen. Vet Approved Protein C Ketoprofen may increase the anticoagulant activities of Protein C. Approved Protein S human Ketoprofen may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Ketoprofen may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Ketoprofen may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when Ketoprofen is combined with PTC299. Investigational Puromycin Ketoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Pyrimethamine The metabolism of Ketoprofen can be decreased when combined with Pyrimethamine. Approved, Vet Approved Quinapril The risk or severity of adverse effects can be increased when Quinapril is combined with Ketoprofen. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketoprofen. Approved Quinine The metabolism of Ketoprofen can be decreased when combined with Quinine. Approved Ramipril The risk or severity of adverse effects can be increased when Ramipril is combined with Ketoprofen. Approved Rescinnamine The risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketoprofen. Approved Resveratrol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol. Experimental, Investigational Reviparin Ketoprofen may increase the anticoagulant activities of Reviparin. Approved Ribostamycin Ketoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved Rifampicin The metabolism of Ketoprofen can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Ketoprofen can be increased when combined with Rifapentine. Approved Rimexolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate. Approved, Investigational Rivaroxaban Ketoprofen may increase the anticoagulant activities of Rivaroxaban. Approved Rosoxacin Ketoprofen may increase the neuroexcitatory activities of Rosoxacin. Approved Rufloxacin Ketoprofen may increase the neuroexcitatory activities of Rufloxacin. Experimental Sabarubicin Ketoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Ketoprofen. Approved Salicylamide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ketoprofen. Approved, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Ketoprofen. Investigational Secobarbital The metabolism of Ketoprofen can be increased when combined with Secobarbital. Approved, Vet Approved Semapimod The risk or severity of adverse effects can be increased when Ketoprofen is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Ketoprofen is combined with Seratrodast. Approved Serrapeptase The risk or severity of adverse effects can be increased when Ketoprofen is combined with Serrapeptase. Investigational Sildenafil The metabolism of Ketoprofen can be decreased when combined with Sildenafil. Approved, Investigational Sisomicin Ketoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Ketoprofen may increase the neuroexcitatory activities of Sitafloxacin. Experimental Sodium phosphate Sodium phosphate may increase the nephrotoxic activities of Ketoprofen. Approved Sorafenib The metabolism of Ketoprofen can be decreased when combined with Sorafenib. Approved, Investigational Sotalol Ketoprofen may decrease the antihypertensive activities of Sotalol. Approved SP1049C Ketoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level. Investigational Sparfloxacin Ketoprofen may increase the neuroexcitatory activities of Sparfloxacin. Approved Spectinomycin Ketoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level. Approved, Vet Approved Spirapril The risk or severity of adverse effects can be increased when Spirapril is combined with Ketoprofen. Approved Spironolactone Ketoprofen may decrease the antihypertensive activities of Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when Ketoprofen is combined with SRT501. Investigational Streptomycin Ketoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Streptozocin Ketoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level. Approved Sulfadiazine The metabolism of Ketoprofen can be decreased when combined with Sulfadiazine. Approved, Vet Approved Sulfamethoxazole The metabolism of Ketoprofen can be decreased when combined with Sulfamethoxazole. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ketoprofen. Approved Sulfisoxazole The metabolism of Ketoprofen can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Ketoprofen. Approved Sulodexide Ketoprofen may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Ketoprofen. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Suxibuzone. Experimental Tacrolimus Ketoprofen may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Ketoprofen. Approved Talinolol Ketoprofen may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Ketoprofen. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tarenflurbil. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Ketoprofen. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen. Approved, Investigational Temafloxacin Ketoprofen may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Temocapril is combined with Ketoprofen. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ketoprofen. Approved Tepoxalin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tepoxalin. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Teriflunomide. Approved Tertatolol Ketoprofen may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid. Approved Ticagrelor The metabolism of Ketoprofen can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Ketoprofen can be decreased when combined with Ticlopidine. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiludronic acid. Approved, Vet Approved Timolol Ketoprofen may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tixocortol. Approved Tobramycin Ketoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolbutamide The metabolism of Ketoprofen can be decreased when combined with Tolbutamide. Approved Tolfenamic Acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid. Approved Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen. Approved Topiroxostat The metabolism of Ketoprofen can be decreased when combined with Topiroxostat. Approved Torasemide Ketoprofen may decrease the diuretic activities of Torasemide. Approved Trandolapril The risk or severity of adverse effects can be increased when Trandolapril is combined with Ketoprofen. Approved Tranilast The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tranilast. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Triamcinolone. Approved, Vet Approved Triamterene Ketoprofen may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Trimethoprim The metabolism of Ketoprofen can be decreased when combined with Trimethoprim. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Triptolide. Investigational Trovafloxacin Ketoprofen may increase the neuroexcitatory activities of Trovafloxacin. Approved, Withdrawn Troxerutin Ketoprofen may increase the anticoagulant activities of Troxerutin. Investigational Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketoprofen. Approved Valproic Acid The metabolism of Ketoprofen can be decreased when combined with Valproic Acid. Approved, Investigational Valrubicin Ketoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level. Approved Valsartan The metabolism of Ketoprofen can be decreased when combined with Valsartan. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Ketoprofen. Approved Voriconazole The metabolism of Ketoprofen can be decreased when combined with Voriconazole. Approved, Investigational Warfarin Ketoprofen may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Ketoprofen may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zafirlukast The metabolism of Ketoprofen can be decreased when combined with Zafirlukast. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zaltoprofen. Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Ketoprofen. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Zofenopril is combined with Ketoprofen. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zomepirac. Withdrawn Zoptarelin doxorubicin Ketoprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Investigational Zorubicin Ketoprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level. Experimental - Food Interactions
- Avoid alcohol.
- Food prolongs rate of absorption and decreases peak plasma concentration. Extent of absorption is not affected.
- Take with food to reduce gastric irritation.
References
- Synthesis Reference
Attilio Citterio, Daniele Fancelli, "Method of preparing ketoprofen." U.S. Patent US4845281, issued December, 1982.
US4845281- General References
- Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. [PubMed:3526298]
- Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. [PubMed:16274258]
- External Links
- Human Metabolome Database
- HMDB15144
- KEGG Drug
- D00132
- KEGG Compound
- C01716
- PubChem Compound
- 3825
- PubChem Substance
- 46505715
- ChemSpider
- 3693
- BindingDB
- 50022271
- ChEBI
- 6128
- ChEMBL
- CHEMBL571
- Therapeutic Targets Database
- DAP000623
- PharmGKB
- PA450149
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Ketoprofen
- ATC Codes
- M01AE53 — Ketoprofen, combinations
- M01AE — Propionic acid derivatives
- M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
- M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
- M — MUSCULO-SKELETAL SYSTEM
- M02AA — Antiinflammatory preparations, non-steroids for topical use
- M02A — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- M02 — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- M — MUSCULO-SKELETAL SYSTEM
- AHFS Codes
- 28:08.04.92
- PDB Entries
- Not Available
- FDA label
- Download (160 KB)
- MSDS
- Download (75.9 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Elan pharmaceutical research corp
- Mylan pharmaceuticals inc
- Watson laboratories inc florida
- Wyeth pharmaceuticals inc
- Heritage pharmaceuticals inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Wyeth ayerst laboratories
- Novartis consumer health inc
- Bayer healthcare llc
- L perrigo co
- Wyeth consumer healthcare
- Packagers
- Aidarex Pharmacuticals LLC
- Apothecary Shop Wholesale
- A-S Medication Solutions LLC
- Bryant Ranch Prepack
- Corepharma LLC
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Elan Pharmaceuticals Inc.
- H.J. Harkins Co. Inc.
- Innoviant Pharmacy Inc.
- Letco Medical Inc.
- Major Pharmaceuticals
- Medisca Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Pharma Pac LLC
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prescription Dispensing Service Inc.
- Professional Co.
- Qualitest
- Rebel Distributors Corp.
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Capsule Oral 50 mg/1 Capsule Oral 50 mg Capsule Oral 75 mg/1 Capsule, extended release Oral 200 mg/1 Tablet Oral 75 mg/1 Tablet, extended release Oral 200 mg Tablet, delayed release Oral 100 mg Tablet, delayed release Oral 50 mg Suppository Rectal 50 mg Capsule, extended release Oral 150 mg Capsule, extended release Oral 200 mg Suppository Rectal 100 mg Kit - Prices
Unit description Cost Unit Ketoprofen powder 43.74USD g Ketoprofen micronized powder 3.84USD g Ketoprofen CR 200 mg 24 Hour Capsule 2.8USD capsule Orudis 75 mg capsule 1.58USD capsule Apo-Keto Sr 200 mg Sustained-Release Tablet 1.46USD tablet Ketoprofen 75 mg capsule 1.12USD capsule Pms-Ketoprofen 100 mg Suppository 1.1USD suppository Ketoprofen 50 mg capsule 1.0USD capsule Apo-Keto-E 100 mg Enteric-Coated Tablet 0.71USD tablet Apo-Keto 50 mg Capsule 0.35USD capsule Apo-Keto-E 50 mg Enteric-Coated Tablet 0.35USD tablet Orudis kt 12.5 mg tablet 0.3USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 94 °C U.S. Patent 3,641,127. water solubility 51 mg/L (at 22 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 3.12 SANGSTER (1993) logS -3.7 ADME Research, USCD pKa 4.45 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.0213 mg/mL ALOGPS logP 3.29 ALOGPS logP 3.61 ChemAxon logS -4.1 ALOGPS pKa (Strongest Acidic) 3.88 ChemAxon pKa (Strongest Basic) -7.5 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 54.37 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 72.52 m3·mol-1 ChemAxon Polarizability 26.56 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9928 Blood Brain Barrier + 0.9382 Caco-2 permeable + 0.8866 P-glycoprotein substrate Non-substrate 0.7132 P-glycoprotein inhibitor I Non-inhibitor 0.9168 P-glycoprotein inhibitor II Non-inhibitor 0.9589 Renal organic cation transporter Non-inhibitor 0.8818 CYP450 2C9 substrate Non-substrate 0.7183 CYP450 2D6 substrate Non-substrate 0.9598 CYP450 3A4 substrate Non-substrate 0.7685 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9604 CYP450 2C19 inhibitor Non-inhibitor 0.9465 CYP450 3A4 inhibitor Non-inhibitor 0.9598 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9438 Ames test Non AMES toxic 0.9801 Carcinogenicity Non-carcinogens 0.6299 Biodegradation Ready biodegradable 0.6701 Rat acute toxicity 2.2378 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9661 hERG inhibition (predictor II) Non-inhibitor 0.9595
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzophenones
- Direct Parent
- Benzophenones
- Alternative Parents
- Diphenylmethanes / Aryl-phenylketones / Phenylpropanoic acids / Benzoyl derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- Benzophenone / Aryl-phenylketone / Diphenylmethane / 2-phenylpropanoic-acid / Benzoyl / Aryl ketone / Ketone / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- benzophenones, oxo monocarboxylic acid (CHEBI:6128)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Parsadaniantz SM, Lebeau A, Duval P, Grimaldi B, Terlain B, Kerdelhue B: Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol. 2000 Aug;12(8):766-73. [PubMed:10929089]
- Kurahashi K, Shirahase H, Nakamura S, Tarumi T, Koshino Y, Wang AM, Nishihashi T, Shimizu Y: Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S21-5. [PubMed:11811354]
- Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718]
- Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823]
- Levoin N, Blondeau C, Guillaume C, Grandcolas L, Chretien F, Jouzeau JY, Benoit E, Chapleur Y, Netter P, Lapicque F: Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen. Biochem Pharmacol. 2004 Nov 15;68(10):1957-69. [PubMed:15476667]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10. [PubMed:10895904]
- Sommerauer M, Ates M, Guhring H, Brune K, Amann R, Peskar BA: Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9. [PubMed:11729362]
- Levoin N, Chretien F, Lapicque F, Chapleur Y: Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7. [PubMed:11814865]
- Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718]
- Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other
- General Function
- Interleukin-8 receptor activity
- Specific Function
- Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activ...
- Gene Name
- CXCR1
- Uniprot ID
- P25024
- Uniprot Name
- C-X-C chemokine receptor type 1
- Molecular Weight
- 39790.735 Da
References
- Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F: 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. [PubMed:15974585]
- Bizzarri C, Pagliei S, Brandolini L, Mascagni P, Caselli G, Transidico P, Sozzani S, Bertini R: Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers. Biochem Pharmacol. 2001 Jun 1;61(11):1429-37. [PubMed:11331079]
- Wang LM, Toyoshima A, Mineshita S, Wang XX, Yamamoto T, Nomura Y, Yang L, Koikei Y, Shiba K, Honda Y: The anti-inflammatory effects of ketoprofen in animal experiments. Drugs Exp Clin Res. 1997;23(1):1-6. [PubMed:9093816]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Bertucci C: Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. Chirality. 2001 Jul;13(7):372-8. [PubMed:11400191]
- Lagrange F, Penhourcq F, Matoga M, Bannwarth B: Binding of ketoprofen enantiomers in various human albumin preparations. J Pharm Biomed Anal. 2000 Oct;23(5):793-802. [PubMed:11022905]
- Li F, Zhou D, Guo X: Study on the protein binding of ketoprofen using capillary electrophoresis frontal analysis compared with liquid chromatography frontal analysis. J Chromatogr Sci. 2003 Mar;41(3):137-41. [PubMed:12725696]
- Zhou D, Li F: [Study of protein binding in ketoprofen using liquid chromatography frontal analysis in comparison with capillary electrophoresis frontal analysis]. Se Pu. 2004 Nov;22(6):601-4. [PubMed:15807110]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Atpase activity, coupled to transmembrane movement of substances
- Specific Function
- May be an organic anion pump relevant to cellular detoxification.
- Gene Name
- ABCC4
- Uniprot ID
- O15439
- Uniprot Name
- Multidrug resistance-associated protein 4
- Molecular Weight
- 149525.33 Da
References
- Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Cihlar T, Ho ES: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55. [PubMed:10929807]
- Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
- Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
- Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
- Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T: Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002 Oct;83(1):57-66. [PubMed:12358729]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
- Gene Name
- SLC22A11
- Uniprot ID
- Q9NSA0
- Uniprot Name
- Solute carrier family 22 member 11
- Molecular Weight
- 59970.945 Da
References
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
- Gene Name
- SLC22A7
- Uniprot ID
- Q9Y694
- Uniprot Name
- Solute carrier family 22 member 7
- Molecular Weight
- 60025.025 Da
References
- Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]
- Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818]
- Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:50